Inditrade Capital’s Group Chairman, Sudip Bandyopadhyay, favors life insurance, particularly LIC, citing its strong quarterly results and long-term potential. While cautious about health insurance due to market uncertainties, he highlights domestic-focused pharma like Mankind Pharma and hospital chains like Apollo Hospitals as promising investments, while advising caution on diagnostic companies due to intense competition.
Infosys buyback: Zerodha’s Nithin Kamath explains the tax trap investors are missing
Infosys’ massive Rs 18,000 crore share buyback is approaching. Zerodha co-founder Nithin Kamath advises investors to understand the tax rules. Gains from the buyback are
November 13, 2025